StonvexLoading…
StonvexStonvexStonvexCore line items from JNJ's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-28 | Annual 2024 2024-12-29 | Annual 2023 2023-12-31 | Annual 2023 2023-10-01 |
|---|---|---|---|---|
Revenue | $94.19B | $88.82B | $85.16B | $21.35B |
Operating Income | $32.58B | $16.69B | $15.06B | $5.22B |
Net Income | $26.80B | $14.07B | $35.15B | $26.03B |
EPS (Diluted) | $11.03 | $5.79 | $13.72 | $10.21 |
Total Assets | $199.21B | $180.10B | $167.56B | Not available |
Total Liabilities | $117.67B | $108.61B | $98.78B | Not available |
Cash & Equivalents | $19.71B | $24.11B | $21.86B | Not available |
Free Cash Flow OCF − CapEx | $19.70B | $19.84B | $18.25B | Not available |
Shares Outstanding | 2.43B | 2.43B | 2.56B | Not available |